Retatrutide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. It is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers. Common dosages range from 4-12 mg weekly (maintenance after titration) administered once weekly.
What Is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. Also known as Eli Lilly triple agonist, GIP/GLP-1/glucagon receptor agonist, it has been studied for its potential effects on substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
The first triple hormone agonist targeting three distinct metabolic pathways simultaneously — producing superior weight loss compared to both semaglutide (single) and tirzepatide (dual) agonists. In the research community, Retatrutide has gained attention for its distinctive profile.
How Does Retatrutide Work?
Activates GIP, GLP-1, and glucagon receptors simultaneously for synergistic metabolic effects: GLP-1R delays gastric emptying and reduces appetite, GIPR enhances glucose-dependent insulin secretion, and glucagon receptor activation increases energy expenditure and hepatic glucose regulation. The triple mechanism produces greater weight loss than dual agonists.
This multi-pathway activity helps explain why Retatrutide shows potential across several different applications.
What Does the Research Say About Retatrutide?
Phase 3 TRIUMPH-4 reported 71.2 lb average weight loss (December 2025). Diabetes trial (TRIUMPH-1) showed 16.8% weight loss. Seven Phase 3 trials with results expected by year-end 2026. Over 20 ongoing clinical trials.
Researchers should consult the latest peer-reviewed literature for the most current findings.
What Is the Recommended Retatrutide Dosage?
Standard Retatrutide dosing: 4-12 mg weekly (maintenance after titration), administered once weekly via subcutaneous injection.
Half-life: approximately 4-5 days. Cycle length: 48+ weeks (continuous therapy in trials).
Use our peptide dosing calculator for exact reconstitution ratios.
Calculate Your Retatrutide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Retatrutide.
Open Calculator →What Are the Side Effects of Retatrutide?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
Retatrutide is not fda-approved as of march 2026. nda filing expected late 2026-early 2027.
Can You Stack Retatrutide With Other Peptides?
Triple agonism provides inherent synergy — not typically stacked with other GLP-1 or GIP agonists.
What Is the Bottom Line on Retatrutide?
Retatrutide is a Triple hormone receptor agonist researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers. Standard protocols use 4-12 mg weekly (maintenance after titration) once weekly for 48+ weeks (continuous therapy in trials).
Source from COA-tested vendors. Read our beginner's guide for more, or use the dosing calculator to plan your protocol.
Complete Guide
Retatrutide : Benefits, Dosage, Side Effects & Research
Related Reading
- Retatrutide Dosage Guide
- Retatrutide Benefits
- Retatrutide Side Effects
- Retatrutide Stacking Guide
- Retatrutide Cycle Guide
- Retatrutide Research
Research-Grade Sourcing
If you're going to research Retatrutide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. It is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
What is the recommended Retatrutide dosage?
Common dosages: 4-12 mg weekly (maintenance after titration) administered once weekly via subcutaneous injection. Cycle length: 48+ weeks (continuous therapy in trials). Half-life: approximately 4-5 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Retatrutide?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
Is Retatrutide safe?
Retatrutide has shown a preliminary safety profile in research. Not FDA-approved as of March 2026. NDA filing expected late 2026-early 2027. All research should follow appropriate safety protocols.